Forum Guidelines: 

This site is not intended to replace the advice of a medical professional, so please do not use the forum to get guidance on clinical, medical issues.  

Please be courteous and do not use obscenity or engage in personal attacks.  This site is overseen by a moderator, and she may delete a comment or restrict your access to the site.  If you have a question, please feel free to send a message  to us and the Leukodystrophy Family Forum moderator will  respond and provide assistance.   We do reserve the right to remove a posting. 

Maria Kefalas
Oct 2, 2017

An open letter to GSK CEO Emma Walmsley


The news that GlaxoSmithKline would divest from rare diseases intrigued industry watchers and left employees at the UK's largest pharmaceutical worried about their livelihoods. But, for patient advocates like myself who had watched GSK become a global leader in the three decade long effort to pioneer gene replacement therapies, the news was devastating.


One of the treatments GSK will sell is a gene therapy for metachromatic leukodystrophy (MLD). My daughter Cal, who is now 7, was diagnosed with MLD at age 2. In three months, Cal lost the ability to walk, talk, and eat.  She uttered her final world five years ago last August: "Daddy."


Today, Cal is paralyzed, blind and receives hospice care.  We are grateful she still laughs and smiles.


Not long after Cal was diagnosed, I learned GSK licensed the MLD gene therapy research from the Telethon Institute in Milan. GSK's involvement in a disease that impacts 1 in 100,000 live births gave me hope. Learning that one of the largest pharmaceutical companies on the planet was going to take on your kid's ultra rare disease was like having your big brother stand up to a schoolyard bully.

Experts in the field called the results from GSK's gene therapy clinical trials for MLD "stunning." Children who should have been near death now attend school and ride bicycles and live remarkably normal lives.


For the past four years, I have worked every single day to get gene therapy to leukodystrophy patients.  


The researchers at GSK took tremendous pride in the project.  When I had the chance to do a "Patient Voices" event at the GSK headquarters in Pennsylvania, there was hardly a dry eye in the house when I told GSK employees about how much hope gene replacement therapy brought to families.


I pointed out that published papers could not show the amazing things I had witnessed, things like kids with MLD eating hot dogs, running outside and talking to their parents. Things that should have been impossible.  Kids were getting a chance to grow up because of GSK. 


The members of  the rare disease team at GSK answered my phone calls, circulated my memos, and endured my nagging and prodding to get gene therapy to the US sooner rather than later. I liked to remind them, "medical miracles are hard work. We are doing this for my daughter Cal and the kids like her." My colleagues at GSK understood that I had to be so relentless because I was honoring Cal and all the kids like her.   You see, there is a notebook in my office with the names of 13 children whose parents I sent condolence cards to.  Every single time a child died, I wrote these parents a letter to promise how I would not stop until gene therapy for MLD was available to children in the US.


Then Ms. Walmsley decided to divest GSK from the gene therapy assets for MLD,  ADA-SCID (Strimvelis), and Wiskott-Aldrich.  


Ms. Walmsley was correct to understand that GSK would never have made money on gene therapy for MLD. During a speech last April, Ms. Walmsley seemed to indicate she would shift gears when she stated GSK would focus on  “real winners” – medicines that generate substantial returns. 


The implication that gene therapy for MLD was not worth GSK's time and resources was wounding.  It also seemed to suggest Ms. Walmsley did not understand the great value of what GSK had already accomplished.


So, let me explain.  The MLD children were teaching researchers how they could tame the HIV virus to build lentiviral vectors. In gene replacement therapy, doctors use vectors, constructed out of viruses stripped of their harmful properties, to infect patients with the working copies of the broken genes that cause a disease.  Gene therapy is more than a cure, it actually slams the brakes on the disease and prevents children with MLD from getting sick.


GSK researchers understood that if they could stop MLD, a devastating neurological disease that attacks the central nervous system, they would be able to take on thousands of other disorders caused by a single faulty gene.  And while GSK, under Ms. Walmsley's leadership  wants to pursue the admirable goal of treating HIV, they did not seem to appreciate how GSK was already using HIV to save children's lives and conquer disease.


I am surprised Ms. Walmsley could not recognize the inherent value of this effort.


If gene replacement therapy sounds amazing and remarkable: it is. But medical miracles don't come cheap. Gene therapies are costly with the price tag ranging from $600k to $1 million dollars per patient.  GSK's senior leadership was right to worry about the bottom-line.  Gene therapy industry leaders will struggle to construct a  sustainable business model for these treatments in the years to come.


Payers and politicians will balk at paying six figures for a treatment that we are still finding the words to describe.  


Given all the uncertainties, especially with the concerns from payers about how much to charge for a medical miracle, it made practical sense for GSK to pull out of gene therapy for rare diseases. But, I would like to point out to Ms. Walmsley how the MLD families had paid an incredible price to advance this research. 


Gene therapy needs time to work, and symptomatic MLD children like my daughter do not benefit from gene therapy. Finding a presymptomatic MLD child meant a family would sacrifice one child to find the other one in time to help them.


Imagine a clinical trial where most every family watched one child succumb to the disease while they fought to save another.  The researchers had faced a Sophie's Choice dilemma in every patient they treated.


And finally, in case you have any doubts about  the lives GSK's gene therapy for MLD has changed, here is a photo of the beautiful children who were treated for MLD with gene therapy.


These children should be on feeding tubes, receiving hospice care, nonverbal and dying. Instead, here they are last May at our gala smiling and laughing and giving everyone who meets them the incredible sense they are witnessing something rare and remarkable.


I am just sorry Ms. Walmsley never had the chance to meet them.


I suspect she would feel differently about the research she did not believe was a "winner."


She would have seen GSK had something so much better: a miracle.


New Posts
  • wrwoodar
    Jul 20

    My son will be 3 yo in october and was diagnosed with spastic diplegia/CP about 2 months ago. Peds neuro ordered MRI to look for signs of CP and there turned out to be white matter injury worrisome for metachromatic leukodystrophy. He has always met his milestones aside from gross motor, primarily with balance and unsteady gait when walking. He does not jump or run but he seems to climb well. Fortunately at this point, he has not shown any regression of skills. Genetic tests are pending. If the tests are negative, has anyone ever encountered being told their child has leukodystrophy and it actually turned out to be CP? Thank you for you responses and support and God bless
  • April Garcia
    Jun 3

    I received a phone call 2 weeks ago from the Seating and Mobility Clinic asking if Jackson (our son) needed to make an appointment to have his adaptive stroller refitted. I told the representative that Jackson had Krabbe Disease and that he wasn’t with us anymore, that we had not been able to be with him since October of 2016. The representative apologized and said “I hope he is getting the care he needs” and we ended the call. Once I hung up I realized that due to my brokenness and inability to verbalize exactly where Jackson is I lead the representative to assume due to the Krabbe Disease that we were no longer able or willing to care for Jackson and that he was being cared for by someone else. I immediately called back and luckily got the same representative and explained that Jackson transferred to heaven and even though that information would not change anything within their company that I could not allow any misunderstanding that we ever gave up on Jackson or that we voluntarily let him go. The representative gasped with new understanding and offered heartfelt condolences. I hung up and let loose a silent soul shaking cry for 2 full minutes before returning back to work.
  • Maria Kefalas
    Jul 29, 2018

    Most days, the grueling routine of caring for a child with leukodystrohy takes a toll. But then, there are organizations and people who can make this journey just a little easier by seeing the beauty of kids with leukodystrophy and welcoming families into their home. The Philadelphia Eagles (and the amazing Julie Hirshey, the director of community relations for the Eagles) have been champions for kids with leukodystrophy and the Calliope Joy Foundation from the very start. We are so proud to host our biennial gala in 2019 at Lincoln Financial Field. And, we were thrilled to learn that the Eagles were hosting our friend Kendall, who has metachromatic leukodystrophy, at this year's Eagles training camp. This photo sums up the amazingness that the Eagles make possible for families in our region. We could not be more proud to work with this incredible organization. Thanks to Cindy Williamson for sharing this photo. Yah, that's Super Bowl MVP Nick Foles with our friend Kendall and her mom Cindy and pop-pop Stanley.

Together, We are stronger

© 2017 Leukodystrophy Family Forum . Proudly created by CAZ Media Design